U.S. markets closed

Curaleaf Holdings, Inc. (CURLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
14.75-0.30 (-1.99%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.05
Bid0.00 x 0
Ask0.00 x 0
Day's Range13.45 - 15.67
52 Week Range2.54 - 18.38
Avg. Volume1,478,229
Market Cap10.069B
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Canopy Growth Is Down 45% From Its Peak

    Why Canopy Growth Is Down 45% From Its Peak

    The largest cannabis company in the world by market capitalization, Canopy Growth (NASDAQ:CGC) has been on a bumpy ride this past month. Since hitting a high of $56.50 a month ago, CGC stock is down to $30. Source: Shutterstock Despite recent periodic short-term gains, it appears CGC stock has lost some momentum over the past month. In this article, I’m going to discuss why I think this is the case.InvestorPlace - Stock Market News, Stock Advice & Trading Tips U.S. Market Access a Big Deal Right Now The potential for U.S. federal legalization has taken the cannabis sector parabolic since the fourth quarter. A political shift to a Democratic House and Senate stoked this sentiment. Accordingly, Canopy Growth has been a beneficiary. At the state level, approximately one in three Americans lives in a state in which cannabis is legal. This has come as a result of recent news about Virginia’s passing of a bill legalizing recreational cannabis use. The first southern state to do so, investors are interpreting this step as a positive one for the passing of a federal legalization bill. 9 Cheap Stocks That Look Like a Bargain This bill has furthered investor excitement for cannabis stocks. Stocks jumped across the board. However, Canopy’s upside on good days for the cannabis sector has been much more muted than its publicly traded peers. Many investors may ask why this has been the case. I believe the real underlying reason Canopy is lagging its U.S. peers is simple. The company’s based in Canada, and because of listing requirements in the U.S., the company has foregone U.S. investments in recent years. Canopy is also crippled by existing banking regulations that exclude cannabis companies from receiving financial services presently. This has made the company’s U.S. expansion more difficult than many of its peers such as Curaleaf Holdings (OTC:CURLF), a leading U.S. cannabis company. Yes, Canopy has a deal in place to acquire U.S. peer Acreage Holdings (OTC:ACRHF) if and when cannabis is made federally legal in the U.S. However, right now, Canopy is locked out of the market directly. Canopy’s large stake in American cannabis player TerrAscend (OTC:TRSSF) is another indirect way Canopy’s gaining momentum in this space. Costly to Gain Traction In New Markets However, investors need to consider the cost of Canopy’s expansion efforts. Because of the head start U.S. peers like Curaleaf have right now, Canopy’s in catch-up mode. Indeed, the additional moves Canopy will need to make to become a major player in the U.S. market, lacking the head start its peers have, will cost a pretty penny. Stock prices have surged as a result of legalization expectations. What may have been well-priced and well-timed acquisitions a year ago now appear daunting. Growing organically takes time and money, both of which are in short supply as operating losses continue to mount for Canopy. Acquiring stakes and having a plan in place to grow organically in the U.S. is great. As is Canopy’s recent announcement of a cannabis-infused beverage line targeted at the U.S. market. However, I think investors are worried these moves are simply not enough right now. Patience Might be Wearing Thin With CGC Stock Personally, I think cannabis investors aren’t waiting around to see who will be able to gobble up market share in the U.S. Rather, investors are focusing on companies like Curaleaf, with size, scale and a vertically integrated footprint from coast to coast. As mentioned, it’s going to be extremely costly for Canopy from here on out to become a dominant global player in cannabis. Canopy’s Canadian business is great, but to be honest, the U.S. market is 10 times larger. Cannabis investors simply won’t care about the Canadian in a year from now if federal legalization materializes in the U.S. It could take a year or more for federal legalization to take hold, if it materializes at all. That’s a long time for investors to wait for Canopy to hit the U.S. market. Sometimes, a first-mover advantage is very valuable. This is certainly one of those cases. On the date of publication, Chris MacDonald did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post Why Canopy Growth Is Down 45% From Its Peak appeared first on InvestorPlace.

  • Tax Tip - Get free, virtual help with your taxes!
    CNW Group

    Tax Tip - Get free, virtual help with your taxes!

    OTTAWA, ON, March 2, 2021 /CNW/ - It's been a challenging year, but we're hoping we can make one thing easier – doing your taxes. It's important to do your taxes on time, every year.

  • Curaleaf Executives to Present at the Benzinga Cannabis Capital Conference
    PR Newswire

    Curaleaf Executives to Present at the Benzinga Cannabis Capital Conference

    Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today announced that Boris Jordan, Curaleaf Executive Chairman, and Sarah-Marie Cole, Curaleaf Regional Vice President of Marketing, will be presenting at the Benzinga Cannabis Capital Conference on February 25, 2021.